公开(公告)号：US20240360085A1

公开(公告)日：2024-10-31

申请号：US18672406

申请日：2024-05-23

Applicant: Kadmon Corporation, LLC

Inventor： Kevin G. Liu ,  Kellen Olszewski ,  Ji-In Kim ,  Masha V. Poyurovsky ,  Koi Morris ,  Xuemei Yu ,  Christophe Lamarque

IPC: C07D239/42 ,  C07D239/94 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D473/34 ,  C07D491/048 ,  C07D491/052 ,  C07D495/04 ,  C07D519/00

CPC classification number: C07D239/42 ,  C07D239/94 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D473/34 ,  C07D491/048 ,  C07D491/052 ,  C07D495/04 ,  C07D519/00

Abstract: This invention provides compounds that modulate glucose uptake activity and cellular transport/uptake of glucose, and particularly GLUT3, but also including but not limited to GLUT1-14 (SLC2A1-SLC2A14). Compounds of the invention are useful for treating diseases, including cancer, autoimmune diseases and inflammation, infectious diseases, and metabolic diseases.

公开(公告)号：US20240351987A1

公开(公告)日：2024-10-24

申请号：US18615563

申请日：2024-03-25

Applicant: Escient Pharmaceuticals, Inc.

Inventor： Marion LANIER ,  Marcus BOEHM ,  Liming HUANG ,  Esther MARTINBOROUGH ,  Marcos SAINZ ,  Brandon SELFRIDGE ,  Adam YEAGER

IPC: C07D215/44 ,  C07D239/94 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D215/44 ,  C07D239/94 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04 ,  C07D487/04

Abstract: Methods are provided for modulating MRGPR X2 generally, or for treating a MRGPR X2 dependent condition more specifically, by contacting the MRGPR X2 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I):




or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6 and Rx are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

公开(公告)号：US20240349605A1

公开(公告)日：2024-10-17

申请号：US18293874

申请日：2022-08-05

Applicant: LG CHEM, LTD.

Inventor： Minjun KIM ,  Dong Hoon LEE ,  Sang Duk SUH ,  Young Seok KIM ,  Da Jung LEE

IPC: H10K85/60 ,  C07C211/54 ,  C07C211/61 ,  C07D209/86 ,  C07D307/91 ,  C07D333/76 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C09K11/06 ,  H10K50/11 ,  H10K101/00

CPC classification number: H10K85/6574 ,  C07C211/54 ,  C07C211/61 ,  C07D209/86 ,  C07D307/91 ,  C07D333/76 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C09K11/06 ,  H10K85/622 ,  H10K85/626 ,  H10K85/633 ,  H10K85/636 ,  H10K85/654 ,  H10K85/6576 ,  C07C2603/18 ,  C07C2603/26 ,  C07C2603/42 ,  C09K2211/1003 ,  C09K2211/1018 ,  H10K50/11 ,  H10K85/6572 ,  H10K2101/90

Abstract: An organic light-emitting device. light emitting device having a light emitting layer including a compound of Chemical Formula 1 and a compound of Chemical Formula 2:




Ar1 and Ar2 are each independently a substituted or unsubstituted C6-60 aryl or C2-60 heteroaryl containing at least one of N, O and S, each Ar3 is independently hydrogen, deuterium, or a substituted or unsubstituted C6-60 aryl or C2-60 heteroaryl containing at least one of N, O and S, and at least one of Ar1, Ar2-Ar3 is a substituted or unsubstituted C16-60 aryl polycyclic aromatic ring,




Ar5 and Ar6 are each substituted or unsubstituted C6-60 aryl or C2-60 heteroaryl containing at least one of N, O and S, and the other substituents are as defined in the specification, provided that Ar3 is not




when Ar3 is an unsubstituted C16-60 aryl polycyclic aromatic ring.

公开(公告)号：US12120950B2

公开(公告)日：2024-10-15

申请号：US18288425

申请日：2022-06-21

Applicant: Shaanxi Lighte Optoelectronics Material Co., Ltd.

Inventor： Zhiyan Jia ,  Heming Zhang ,  Yingwen Li ,  Youngkook Kim

IPC: H10K85/60 ,  C07C211/54 ,  C07C211/61 ,  C07D209/86 ,  C07D209/88 ,  C07D307/91 ,  C07D333/76 ,  C07D409/12 ,  C07F7/08 ,  C09K11/06 ,  H10K50/15 ,  H10K85/40

CPC classification number: H10K85/633 ,  C07C211/54 ,  C07C211/61 ,  C07D209/86 ,  C07D209/88 ,  C07D307/91 ,  C07D333/76 ,  C07D409/12 ,  C07F7/081 ,  C09K11/06 ,  H10K85/40 ,  H10K85/636 ,  C07C2603/18 ,  C07C2603/97 ,  C09K2211/1011 ,  C09K2211/1014 ,  C09K2211/1018 ,  H10K50/156 ,  H10K85/615 ,  H10K85/624 ,  H10K85/626 ,  H10K85/6572 ,  H10K85/6574 ,  H10K85/6576

Abstract: The present application relates to an organic compound, an electronic element and an electronic apparatus. A structural formula of the organic compound of the present application is represented by Formula I, and when used in an organic electroluminescent device, the organic compound may significantly improve the performance of the device.

公开(公告)号：US12116360B2

公开(公告)日：2024-10-15

申请号：US18400275

申请日：2023-12-29

Applicant: DUK SAN NEOLUX CO., LTD.

Inventor： Soo Yeon Kim ,  Hye Jeong Kim ,  Hyung Dong Lee ,  Jung Geun Lee

IPC: C07D407/12 ,  C07D307/91 ,  C07D333/76 ,  C07D409/12 ,  H10K50/11 ,  H10K50/15 ,  H10K50/16 ,  H10K50/17 ,  H10K85/60

CPC classification number: C07D407/12 ,  C07D307/91 ,  C07D333/76 ,  C07D409/12 ,  H10K50/11 ,  H10K50/15 ,  H10K50/16 ,  H10K50/171 ,  H10K85/6574 ,  H10K85/6576

Abstract: Provided are a compound represented by Formula (1) capable of improving the light-emitting efficiency, stability, and lifespan of an element; a composition comprising the same; an organic electronic element using same; and an electronic device thereof.

公开(公告)号：US12116356B2

公开(公告)日：2024-10-15

申请号：US18106103

申请日：2023-02-06

Applicant: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

Inventor： Yinsheng Zhang ,  Wangwei Ao ,  Yuan Li ,  Hui Wang ,  Hangzhou Shen ,  Jie Ni ,  Huan Zhang ,  Jie Wu ,  Li Zhang ,  Kai Cao ,  Peng Lu ,  Xushi Liu ,  Jie Wang ,  Tianxiao Zhao ,  Xingfeng Ge ,  Dandan Lu ,  Shuo Chen ,  Xueqin Ma ,  Wei Shi ,  Xiaojin Wang ,  Hongjiang Xu

IPC: C07D401/12 ,  C07D207/34 ,  C07D405/12 ,  C07D409/12

CPC classification number: C07D401/12 ,  C07D207/34 ,  C07D405/12 ,  C07D409/12

Abstract: A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.

公开(公告)号：US12108662B2

公开(公告)日：2024-10-01

申请号：US16304346

申请日：2017-05-24

Applicant: DUK SAN NEOLUX CO., LTD.

Inventor： Soung Yun Mun ,  Jae Taek Kwon ,  Jong Gwang Park ,  Yun Suk Lee ,  Won Sam Kim ,  Seul Gi Kim ,  Jin Bae Jeon ,  Jung Hwan Park

IPC: H10K85/60 ,  C07C211/54 ,  C07D209/82 ,  C07D307/91 ,  C07D333/76 ,  C07D409/12 ,  C09K11/06 ,  H10K50/00 ,  H10K50/11 ,  H10K50/15 ,  H10K50/17 ,  H10K99/00 ,  H10K101/10

CPC classification number: H10K85/636 ,  C07C211/54 ,  C07D209/82 ,  C07D307/91 ,  C07D333/76 ,  C07D409/12 ,  C09K11/06 ,  H10K50/00 ,  H10K50/11 ,  H10K85/622 ,  H10K85/626 ,  H10K85/633 ,  H10K85/654 ,  H10K85/6572 ,  H10K99/00 ,  H10K50/15 ,  H10K50/17 ,  H10K85/6574 ,  H10K85/6576 ,  H10K2101/10

Abstract: Provided are an organic electronic element and an electronic device therefor, wherein the organic electronic element has a mixture of a compound according to the present invention used as material for an organic layer thereof, thereby enabling the achievement of high light-emitting efficiency and low driving voltage of the organic electronic element, and enabling the life of the element to be greatly extended.

公开(公告)号：US20240317727A1

公开(公告)日：2024-09-26

申请号：US18662751

申请日：2024-05-13

Applicant: Duke University ,  Sisu Pharma, Inc.

Inventor： Dennis J. Thiele ,  Sean O'Brien

IPC: C07D413/12 ,  C07C275/40 ,  C07C311/08 ,  C07C317/14 ,  C07D257/04 ,  C07D265/30 ,  C07D285/14 ,  C07D307/81 ,  C07D333/66 ,  C07D333/76 ,  C07D335/06 ,  C07D409/12

CPC classification number: C07D413/12 ,  C07C275/40 ,  C07C311/08 ,  C07C317/14 ,  C07D257/04 ,  C07D265/30 ,  C07D285/14 ,  C07D307/81 ,  C07D333/66 ,  C07D333/76 ,  C07D335/06 ,  C07D409/12 ,  C07C2601/16

Abstract: This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

公开(公告)号：US20240316017A1

公开(公告)日：2024-09-26

申请号：US18569157

申请日：2022-06-24

Applicant: LG CHEM, LTD.

Inventor： Young Jin HAM ,  Joong Heui CHO ,  Hong Bin YOON ,  Jung Joon KIM ,  Young Shin KWAK ,  Gyeong Hwan KIM ,  Ju Hyun LEE

IPC: A61K31/4439 ,  A61K31/4436 ,  A61K31/506 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14 ,  C07D409/12 ,  C07D417/12

CPC classification number: A61K31/4439 ,  A61K31/4436 ,  A61K31/506 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14 ,  C07D409/12 ,  C07D417/12

Abstract: The present invention relates to a novel compound as a protein kinase inhibitor, particularly, a RON inhibitor.

公开(公告)号：US12098130B2

公开(公告)日：2024-09-24

申请号：US18327986

申请日：2023-06-02

Applicant: 89BIO LTD

Inventor： Nadine C. Becknell ,  Reddeppa Reddy Dandu ,  Bruce D. Dorsey ,  Dimitar B. Gotchev ,  Robert L. Hudkins ,  Linda Weinberg ,  Craig A. Zificsak ,  Allison Zulli

IPC: C07D211/44 ,  C07D211/54 ,  C07D211/58 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/02 ,  C07D471/04 ,  C07D471/08 ,  C07D491/048 ,  C07D495/02 ,  C07D495/04

CPC classification number: C07D211/44 ,  C07D211/54 ,  C07D211/58 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/02 ,  C07D471/04 ,  C07D471/08 ,  C07D491/048 ,  C07D495/02 ,  C07D495/04

Abstract: Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.